• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性出血性毛细血管扩张症患者的诊断延迟时间长:基于问卷调查的回顾性研究。

A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study.

机构信息

Geriatric Unit and Rare Disease Center, University Hospital of Bari, Bari, Italy.

出版信息

Orphanet J Rare Dis. 2012 Jun 7;7:33. doi: 10.1186/1750-1172-7-33.

DOI:10.1186/1750-1172-7-33
PMID:22676497
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3458963/
Abstract

BACKGROUND

The difficulty in establishing a timely correct diagnosis is a relevant matter of concern for several rare diseases. Many rare-disease-affected patients suffer from considerable diagnostic delay, mainly due to their poor knowledge among healthcare professionals, insufficient disease awareness among patients' families, and lack of promptly available diagnostic tools. Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal-dominantly inherited vascular dysplasia, affecting 1:5,000-10,000 patients. HHT is characterized by high variability of clinical manifestations, which show remarkable overlapping with several common diseases.

AIM

To perform a detailed analysis concerning the diagnostic time lag occurring in patients with HHT, defined as the time period spanning from the first clinical manifestation to the attainment of a definite, correct diagnosis.

METHODS

A questionnaire was administered to the HHT patients previously recruited from 2000 and 2009. Clinical onset, first referral to a physician for disease manifestations, and first correct diagnosis of definite HHT were collected. Eventual misdiagnosis at first referral and serious complications occurring throughout the time elapsing between disease onset and definite diagnosis were also addressed.

RESULTS

In the 233 respondents, the clinical onset of disease occurred at an age of 14.1 yrs, while the age of first referral and the age of first definite diagnosis of HHT were 29.2 yrs and 40.1 yrs, respectively. Only 88/233 patients received a correct diagnosis at first counseling. Thus, the diagnostic time lag, represented by the time elapsing from disease onset and first definite diagnosis of HHT, proved to be 25.7 yrs. Twenty-two patients suffered from severe complications during this time interval. The diagnostic delay was significantly longer (p < 0.001) in index patients (first patients who attained definite HHT diagnosis in a given family) than in non-index patients (relative of index patients). The diagnostic time lag was also significantly associated with education grade (p < 0.001).

CONCLUSIONS

Our data report for the first time a systematic inquiry of diagnostic delay in HHT showing that patients receive a definite diagnosis only after nearly three decades from disease onset. Concerted efforts are still to be made to increase awareness of this disease among both families and physicians.

摘要

背景

对于许多罕见病来说,难以及时做出正确诊断是一个令人关注的问题。许多受罕见病影响的患者都经历了相当长的诊断延迟,这主要是由于医疗保健专业人员对此病的了解不足,患者家属对此病的认识不足,以及缺乏及时可用的诊断工具。遗传性出血性毛细血管扩张症(HHT)是一种常染色体显性遗传性血管发育不良,影响每 5000-10000 人中的 1 人。HHT 的临床表现具有高度可变性,与几种常见疾病有显著重叠。

目的

对 HHT 患者的诊断时间延迟进行详细分析,将其定义为从首次临床表现到获得明确、正确诊断的时间段。

方法

对 2000 年和 2009 年以前招募的 HHT 患者进行问卷调查。收集疾病发作时的临床起病、首次因疾病表现就诊于医生、首次明确诊断为 HHT 的时间。还记录了首次就诊时的误诊情况以及从发病到明确诊断期间发生的严重并发症。

结果

在 233 名应答者中,疾病的临床起病年龄为 14.1 岁,而首次就诊年龄和首次明确诊断为 HHT 的年龄分别为 29.2 岁和 40.1 岁。只有 88/233 例患者在首次咨询时得到了正确的诊断。因此,从疾病发作到首次明确诊断为 HHT 的诊断时间延迟为 25.7 年。在此期间,22 例患者发生严重并发症。指数患者(在一个家族中首次获得明确 HHT 诊断的患者)的诊断延迟明显长于非指数患者(指数患者的亲属)(p<0.001)。诊断时间延迟与教育程度显著相关(p<0.001)。

结论

我们首次报告了一项关于 HHT 诊断延迟的系统研究,表明患者在发病近 30 年后才得到明确诊断。仍需做出一致努力,提高家庭和医生对该病的认识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/222166fc7f97/1750-1172-7-33-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/8d5c62dcf8aa/1750-1172-7-33-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/1882a103ea3d/1750-1172-7-33-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/1027bf0e187c/1750-1172-7-33-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/222166fc7f97/1750-1172-7-33-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/8d5c62dcf8aa/1750-1172-7-33-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/1882a103ea3d/1750-1172-7-33-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/1027bf0e187c/1750-1172-7-33-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5629/3458963/222166fc7f97/1750-1172-7-33-4.jpg

相似文献

1
A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study.遗传性出血性毛细血管扩张症患者的诊断延迟时间长:基于问卷调查的回顾性研究。
Orphanet J Rare Dis. 2012 Jun 7;7:33. doi: 10.1186/1750-1172-7-33.
2
Screening for pulmonary and cerebral arteriovenous malformations in children with hereditary haemorrhagic telangiectasia.对遗传性出血性毛细血管扩张症患儿进行肺和脑动静脉畸形筛查。
Eur Respir J. 2009 Oct;34(4):875-81. doi: 10.1183/09031936.00030009. Epub 2009 Apr 22.
3
Silent threat? A retrospective study of screening practices for pulmonary arteriovenous malformations in patients with hereditary haemorrhagic telangiectasia.无声的威胁?遗传性出血性毛细血管扩张症患者肺动静脉畸形筛查实践的回顾性研究。
Rhinology. 2012 Sep;50(3):277-83. doi: 10.4193/Rhino12.043.
4
Experience of the Irish National Centre for hereditary haemorrhagic telangiectasia 2003-2008.爱尔兰国家遗传性出血性毛细血管扩张症中心 2003-2008 年的经验。
Respir Med. 2010 Aug;104(8):1218-24. doi: 10.1016/j.rmed.2010.03.003. Epub 2010 Apr 1.
5
Hereditary haemorrhagic telangiectasia, an Australian cohort: clinical and investigative features.遗传性出血性毛细血管扩张症,澳大利亚队列研究:临床及检查特征
Intern Med J. 2014 Jul;44(7):639-44. doi: 10.1111/imj.12457.
6
Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures.遗传性出血性毛细血管扩张症:临床表现与诊断方法的最新进展
Wien Klin Wochenschr. 2006 Mar;118(3-4):72-80. doi: 10.1007/s00508-006-0561-x.
7
Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia.遗传性出血性毛细血管扩张症患者中按基因型分类的临床症状
J Intern Med. 2005 Oct;258(4):349-55. doi: 10.1111/j.1365-2796.2005.01555.x.
8
A retrospective cohort study on European Reference Network for Rare Vascular Diseases 5 outcome measures for Hereditary Haemorrhagic Telangiectasia in Denmark.丹麦遗传性出血性毛细血管扩张症欧洲参考网络 5 项结局指标的回顾性队列研究。
Orphanet J Rare Dis. 2022 Jan 6;17(1):8. doi: 10.1186/s13023-021-02160-1.
9
Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents.儿童和青少年遗传性出血性毛细血管扩张症的表现
Eur Arch Otorhinolaryngol. 2006 Jan;263(1):53-61. doi: 10.1007/s00405-005-0956-8. Epub 2005 Jun 24.
10
Central nervous system arteriovenous malformations with hereditary hemorrhagic telangiectasia: report of a family with three cases.伴有遗传性出血性毛细血管扩张症的中枢神经系统动静脉畸形:1例家族性3例报告
Surg Neurol. 1994 Sep;42(3):234-9. doi: 10.1016/0090-3019(94)90269-0.

引用本文的文献

1
Assessing racial differences in North American hereditary hemorrhagic telangiectasia study recruitment and care.评估北美遗传性出血性毛细血管扩张症研究招募与护理中的种族差异。
Orphanet J Rare Dis. 2025 Aug 28;20(1):461. doi: 10.1186/s13023-025-03883-1.
2
The effect of the COVID-19 pandemic on epistaxis and anaemia in patients with hereditary haemorrhagic telangiectasia (HHT) in central South Africa.新冠疫情对南非中部遗传性出血性毛细血管扩张症(HHT)患者鼻出血和贫血的影响。
Orphanet J Rare Dis. 2025 Jul 16;20(1):364. doi: 10.1186/s13023-025-03777-2.
3
Rendu-Osler disease, a cause of recurrent epistaxis: a case report.

本文引用的文献

1
Hereditary hemorrhagic telangiectasia: children need screening too.遗传性出血性毛细血管扩张症:儿童也需要筛查。
Pediatr Nurs. 2011 Jul-Aug;37(4):163-8; quiz 169.
2
Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia.为什么在家族中对常染色体显性遗传病的基因筛查未得到充分应用?以遗传性出血性毛细血管扩张症为例。
Genet Med. 2011 Sep;13(9):812-20. doi: 10.1097/GIM.0b013e31821d2e6d.
3
Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment.遗传性出血性毛细血管扩张症:病理生理学、诊断与治疗。
遗传性出血性毛细血管扩张症,复发性鼻出血的一个病因:病例报告
J Med Life. 2025 Apr;18(4):397-401. doi: 10.25122/jml-2025-0070.
4
Specifications of the ACMG/AMP Variant Curation Guidelines for Hereditary Hemorrhagic Telangiectasia Genes- and .遗传性出血性毛细血管扩张症基因的ACMG/AMP变异整理指南规范 - 以及
Hum Mutat. 2024 May 18;2024:3043736. doi: 10.1155/2024/3043736. eCollection 2024.
5
Quantifying the burden of hereditary hemorrhagic telangiectasia on quality of life and psychological health: a cross-sectional study.量化遗传性出血性毛细血管扩张症对生活质量和心理健康的影响:一项横断面研究。
Orphanet J Rare Dis. 2025 Mar 7;20(1):109. doi: 10.1186/s13023-025-03620-8.
6
Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey.罕见病患者的诊断时间和诊断延迟的决定因素:罕见病晴雨表回顾性患者调查结果。
Eur J Hum Genet. 2024 Sep;32(9):1116-1126. doi: 10.1038/s41431-024-01604-z. Epub 2024 May 16.
7
Personalised stroke evaluation and management: tailoring individualised patient care for hereditary haemorrhagic telangiectasia.个体化卒中评估与管理:遗传性出血性毛细血管扩张症患者的个体化护理。
BMJ Case Rep. 2024 Apr 4;17(4):e257682. doi: 10.1136/bcr-2023-257682.
8
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia.贝伐珠单抗治疗遗传性出血性毛细血管扩张症患者的成本效益分析。
Blood Adv. 2024 Jun 11;8(11):2835-2845. doi: 10.1182/bloodadvances.2024012589.
9
[Prevalencia de la Telangiectasia Hemorrágica Hereditaria: estudio de base poblacional en la Comunitat Valenciana (España).].[遗传性出血性毛细血管扩张症的患病率:西班牙巴伦西亚自治区的人群基础研究。]
Rev Esp Salud Publica. 2023 Nov 15;97:e202311096.
10
Phenotypic presentation of Mendelian disease across the diagnostic trajectory in electronic health records.基于电子健康记录的孟德尔疾病在诊断轨迹上的表型呈现。
Genet Med. 2023 Oct;25(10):100921. doi: 10.1016/j.gim.2023.100921. Epub 2023 Jun 17.
Blood Rev. 2010 Nov;24(6):203-19. doi: 10.1016/j.blre.2010.07.001. Epub 2010 Sep 25.
4
Cushing's syndrome: why is diagnosis so difficult?库欣综合征:为何诊断如此困难?
Rev Endocr Metab Disord. 2010 Jun;11(2):105-16. doi: 10.1007/s11154-010-9127-3.
5
Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).遗传性出血性毛细血管扩张症(HHT)中新型生物标志物 Ang-2 和 sEng 血浆水平降低。
Clin Chim Acta. 2010 Apr 2;411(7-8):494-9. doi: 10.1016/j.cca.2009.12.023. Epub 2010 Jan 11.
6
Relapsing polychondritis: case report and literature review.复发性多软骨炎:病例报告及文献综述
Pol Arch Med Wewn. 2009 Oct;119(10):680-3.
7
Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia.血管内皮生长因子对遗传性出血性毛细血管扩张症患儿表型严重程度的影响。
J Pediatr Hematol Oncol. 2009 Aug;31(8):577-82. doi: 10.1097/MPH.0b013e3181a1c104.
8
International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.国际遗传性出血性毛细血管扩张症诊断和管理指南。
J Med Genet. 2011 Feb;48(2):73-87. doi: 10.1136/jmg.2009.069013. Epub 2009 Jun 23.
9
An update on autoinflammatory diseases. New concepts for new and old diseases.自身炎症性疾病的最新进展。新旧疾病的新概念。
Clin Exp Rheumatol. 2009 Mar-Apr;27(2):354-65.
10
Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient.与时间赛跑:识别、鉴别、诊断及转诊肌萎缩侧索硬化症患者。
Ann Neurol. 2009 Jan;65 Suppl 1:S10-6. doi: 10.1002/ana.21545.